Galapagos doses first psoriatic arthritis patient with filgotinib
April 05 2017 - 4:01PM
First dosing triggers $10 million milestone payment
from GileadMechelen, Belgium; 5 April 2017, regulated
information - Galapagos NV (Euronext & NASDAQ: GLPG)
announces dosing of the first patient with psoriatic
arthritis in the EQUATOR Phase 2 study. This achievement
triggers a $10 million milestone payment from Gilead to
Galapagos.
The EQUATOR Phase 2 study will be a
multi-center, randomized, double-blind, placebo-controlled study to
assess the safety and efficacy of the selective JAK1 inhibitor
filgotinib in adult patients with moderately to severely active
psoriatic arthritis.
Galapagos and Gilead entered into a global
collaboration for the development and commercialization of
filgotinib in inflammatory indications. In addition to the EQUATOR
Phase 2 study in psoriatic arthritis and the TORTUGA Phase 2 study
in ankylosing spondylitis led by Galapagos, Gilead initiated the
FINCH Phase 3 program in rheumatoid arthritis, the DIVERSITY Phase
3 study in Crohn's disease, the SELECTION Phase 2b/3 study in
ulcerative colitis in 2016 and leads the Phase 2 study in Sjögren's
syndrome.
Filgotinib is an investigational drug and its efficacy and
safety have not been established.For information about the studies
with filgotinib: www.clinicaltrials.govFor more information about
filgotinib: www.glpg.com/filgotinib
About GalapagosGalapagos (Euronext & NASDAQ: GLPG) is
a clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action. Our pipeline comprises Phase 3, Phase 2, Phase 1,
pre-clinical, and discovery programs in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We
have discovered and developed filgotinib: in collaboration with
Gilead we aim to bring this JAK1-selective inhibitor for
inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 510
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& CorporateCommunications+1 781 460 1784 |
Director
Communications +31 6 53 591 999 communications@glpg.com |
Paul van der
HorstDirector IR & Business Development+31 6 53 725 199 |
|
ir@glpg.com |
|
This press release contains inside information within the
meaning of Regulation (EU) No 596/2014 of the European Parliament
and of the Council of 16 April 2014 on market abuse (market abuse
regulation).
Forward-looking statementsThis release may contain
forward-looking statements, including statements regarding
Galapagos' strategic ambitions, the anticipated timing of clinical
studies with filgotinib, and the progression and results of such
studies. Galapagos cautions the reader that forward-looking
statements are not guarantees of future performance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent
with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from the ongoing and planned clinical research
programs may not support registration or further development of
Galapagos' product candidates due to safety, efficacy or other
reasons), Galapagos' reliance on collaborations with third parties
(including its collaboration partner for filgotinib, Gilead), and
estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities
and Exchange Commission (SEC) filings and reports, including in
Galapagos' most recent annual report on form 20-F filed with the
SEC and subsequent filings and reports filed by Galapagos with the
SEC. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements, unless specifically required by law or regulation.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/1b9a91d1-e857-4133-93a8-a6a71da87c8e
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Oct 2023 to Oct 2024